The Pharmacogenetics of Calcineurin Inhibitor-Related NephrotoxicityHESSELINK, Dennis A; BOUAMAR, Rachida; VAN GELDER, Teun et al.Therapeutic drug monitoring. 2010, Vol 32, Num 4, pp 387-393, issn 0163-4356, 7 p.Article

Inhibitory Effect of Tacrolimus on p38 Mitogen-Activated Protein Kinase Signaling in Kidney Transplant Recipients Measured by Whole-Blood Phosphospecific Flow CytometryVAFADARI, Ramin; HESSELINK, Dennis A; CADOGAN, Monique M et al.Transplantation. 2012, Vol 93, Num 12, pp 1245-1251, issn 0041-1337, 7 p.Article

New rat model that phenotypically resembles autosomal recessive polycystic kidney diseaseNAUTA, Jeroen; GOEDBLOED, Miriam A; VAN HERCK, Harry et al.Journal of the American Society of Nephrology. 2000, Vol 11, Num 12, pp 2272-2284, issn 1046-6673Article

Measurement of Cyclosporine A in RatTissues and Human Kidney Transplant Biopsies-A Method Suitable for Small (<1 mg) SamplesNOLL, Benjamin D; COLLER, Janet K; SOMOGYI, Andrew A et al.Therapeutic drug monitoring. 2011, Vol 33, Num 6, pp 688-693, issn 0163-4356, 6 p.Article

Genetic polymorphisms of the CYP3A4, CTP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimusHESSELINK, Dennis A; VAN SCHAIK, Ron H. N; VAN DER HEIDEN, Ilse P et al.Clinical pharmacology and therapeutics. 2003, Vol 74, Num 3, pp 245-254, issn 0009-9236, 10 p.Article

Validation of an LC―MS/MS Method to Measure Tacrolimus in Rat Kidney and Liver Tissue and Its Application to Human Kidney BiopsiesNOLL, Benjamin D; COLLER, Janet K; SOMOGYI, Andrew A et al.Therapeutic drug monitoring. 2013, Vol 35, Num 5, pp 617-623, issn 0163-4356, 7 p.Article

CYP3A5 Genotype Is Not Related to the Intrapatient Variability of Tacrolimus ClearancePASHAEE, Nilufar; BOUAMAR, Rachida; HESSELINK, Dennis A et al.Therapeutic drug monitoring. 2011, Vol 33, Num 3, pp 369-371, issn 0163-4356, 3 p.Article

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genesHESSELINK, Dennis A; VAN GELDER, Teun; VAN SCHAIK, Ron H. N et al.Clinical pharmacology and therapeutics. 2004, Vol 76, Num 6, pp 545-556, issn 0009-9236, 12 p.Article

Genetic Polymorphisms in ABCB1 Influence the Pharmacodynamics of TacrolimusVAFADARI, Ramin; BOUAMAR, Rachida; HESSELINK, Dennis A et al.Therapeutic drug monitoring. 2013, Vol 35, Num 4, pp 459-465, issn 0163-4356, 7 p.Article

Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipientsBOUAMAR, Rachida; HESSELINK, Dennis A; VAN SCHAIK, Ron H. N et al.Pharmacogenetics and genomics (Print). 2012, Vol 22, Num 6, pp 399-407, issn 1744-6872, 9 p.Article

The new CYP3A4 intron 6 C>T polymorphism (CYP3A4^*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patientsEVENS, Laure; BOUAMAR, Rachida; HESSELINK, Dennis A et al.Pharmacogenetics and genomics (Print). 2012, Vol 22, Num 5, pp 373-380, issn 1744-6872, 8 p.Article

Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2HESSELINK, Dennis A; VAN HEST, Reinier M; MATHOT, Ron A. A et al.American journal of transplantation (Print). 2005, Vol 5, Num 5, pp 987-994, issn 1600-6135, 8 p.Article

Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant PatientsELENS, Laure; HESSELINK, Dennis A; VAN SCHAIK, Ron H. N et al.Therapeutic drug monitoring. 2014, Vol 36, Num 1, pp 71-79, issn 0163-4356, 9 p.Article

The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ TransplantationHESSELINK, Dennis A; BOUAMAR, Rachida; ELENS, Laure et al.Clinical pharmacokinetics. 2014, Vol 53, Num 2, pp 123-139, issn 0312-5963, 17 p.Article

CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipientsHESSELINK, Dennis A; VAN SCHAIK, Ron H. N; MAMELOK, Richard D et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 4, pp 339-348, issn 1744-6872, 10 p.Article

Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are Not Associated With Cyclosporine Pharmacokinetics Nor With Cyclosporine Clinical End Points After Renal TransplantationBOUAMAR, Rachida; HESSELINK, Dennis A; VAN SCHAIK, Ron H. N et al.Therapeutic drug monitoring. 2011, Vol 33, Num 2, pp 178-184, issn 0163-4356, 7 p.Article

A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant RecipientsELENS, Laure; BOUAMAR, Rachida; HESSELINK, Dennis A et al.Clinical chemistry (Baltimore, Md.). 2011, Vol 57, Num 11, pp 1574-1583, issn 0009-9147, 10 p.Article

Clinical outcome after cyclosporine dose reduction based on C₂ levels in long-term liver transplant patientsTHA-IN, Thanyalak; HESSELINK, Dennis A; TILANUS, Hugo W et al.Clinical transplantation. 2005, Vol 19, Num 4, pp 537-542, issn 0902-0063, 6 p.Article

The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cellsHESSELINK, Dennis A; BETJES, Michiel G. H; VERKADE, Martijn A et al.Nephrology, dialysis, transplantation (Print). 2005, Vol 20, Num 9, pp 1868-1873, issn 0931-0509, 6 p.Article

Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroidsHESSELINK, Dennis A; NGYUEN, Hien; WABBIJN, Marike et al.British journal of clinical pharmacology. 2003, Vol 56, Num 3, pp 327-330, issn 0306-5251, 4 p.Article